| 000 | a | ||
|---|---|---|---|
| 999 |
_c19480 _d19480 |
||
| 003 | OSt | ||
| 005 | 20230530164735.0 | ||
| 008 | 230530b xxu||||| |||| 00| 0 eng d | ||
| 040 |
_aAIKTC-KRRC _cAIKTC-KRRC |
||
| 100 |
_921016 _aVedam, Venkata Aksheena Varahi |
||
| 245 | _aHomocysteine levels and clinical outcomes in schizophrenia—a pilot randomized controlled trial | ||
| 250 | _aVol.13(3), Sep | ||
| 260 |
_aNew Delhi _bSAGE _c2022 |
||
| 300 | _a284-292p. | ||
| 520 | _aObjectives:To find out the relation between homocysteine levels in peripheral blood and the effectiveness as well as the safety of haloperidol and olanzapine in schizophrenia treatment. Materials and Methods:A prospective randomized parallel-group open-label interventional clinical trial was conducted on 40 mild to moderate schizophrenia patients. To compare the efficacy of olanzapine and haloperidol Brief Psychiatric Rating Scale (BPRS) score was used. Homocysteine levels of peripheral blood and Abnormal Involuntary Movement Scale scores were evaluated. Results:BPRS score improved in both groups on day 14 and day 28. But significantly more with olanzapine (P value =.001). The olanzapine group showed a higher reduction (13.91±0.47 to 9.74±0.5) in homocysteine levels than the haloperidol group. Also, the BPRS scores negatively correlated (r = –0.66) to homocysteine levels. Conclusion:Therefore, our study shows that peripheral blood homocysteine levels can be used to predict and assess the treatment outcome in schizophrenia patients. Biomarker driven approach in schizophrenia will allow the patients to be treated promptly with the right drug. In this light, personalized treatment holds great potential in the future. | ||
| 650 | 0 |
_94774 _aPHARMACOLOGY |
|
| 700 |
_921017 _aGhanta, Mohan Krishna |
||
| 773 | 0 |
_x0976-500X _tJournal of pharmacology and pharmacotherapeutics _dNew Delhi SAGE Publications |
|
| 856 |
_uhttps://journals.sagepub.com/doi/epub/10.1177/0976500X221128649 _yClick here |
||
| 942 |
_2ddc _cAR |
||